FDA Warns Against Long-Term Use Of Osteoporosis Drugs
Prolonged use of popular osteoporosis drugs such as Merck & Co. Inc.'s Fosamax and Novartis AG's Reclast might best be limited to the highest-risk patients because of concern over serious side...To view the full article, register now.
Already a subscriber? Click here to view full article